{"protocolSection": {"identificationModule": {"nctId": "NCT00922441", "orgStudyIdInfo": {"id": "A657-BR-CT-203"}, "organization": {"fullName": "Boryung Pharmaceutical Co., Ltd", "class": "INDUSTRY"}, "briefTitle": "A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657\u2022K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension", "officialTitle": "A Randomized, Double-blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657\u2022K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2018-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-12"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-06-16", "studyFirstSubmitQcDate": "2009-06-16", "studyFirstPostDateStruct": {"date": "2009-06-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-01-16", "resultsFirstSubmitQcDate": "2018-01-16", "resultsFirstPostDateStruct": {"date": "2018-02-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-02-19", "lastUpdatePostDateStruct": {"date": "2018-03-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boryung Pharmaceutical Co., Ltd", "class": "INDUSTRY"}, "collaborators": [{"name": "Seoul National University Hospital", "class": "OTHER"}, {"name": "Kyungpook National University Hospital", "class": "OTHER"}, {"name": "Catholic Medical Center", "class": "OTHER"}, {"name": "Inje University", "class": "OTHER"}, {"name": "Chonnam National University Hospital", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657\u2022K) during 24 hours by dose in patients with mild to moderate essential hypertension.", "detailedDescription": "Fimasartan(BR-A-657-K), a selective blocker of AT1 receptor subtype, showed the rapid and potent antihypertensive effect in many hypertensive models. Phase I study, Fimasartan(BR-A-657-K) 20mg \\~ 480mg single dosing with healthy subjects, demonstrated that the Fimasartan(BR-A-657-K) was very safe and well tolerated. Another phase I study, Fimasartan(BR-A-657-K) 120mg and 360mg dosing for 7 days, also showed that Fimasartan(BR-A-657-K) was safe and tolerable though one temporal adverse event was observed in high dose.\n\nA Randomized, Double-blind, Valsartan-referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657\u2022K) during 24hoursby dose in Patients with Mild to Moderate Essential Hypertension.\n\nApproximately 90 patients will be enrolled over 12 months in 5 centers nationwide.\n\nAfter 2 weeks of placebo run-in period, all subjects will be randomized into one of the following 3 groups. Subjects will take test/control drug for 8 weeks of treatment period.\n\nIf subjects take any antihypertensive medications before screening, the subjects will have 1 week of wash-out period.\n\nGroup I : Fimasartan 60mg group. Group II : Fimasartan 120mg group Group III : Valsartan 80mg group"}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Fimasartan", "Essential Hypertension", "24hour ABPM", "Population PK"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 92, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fimasartan 1", "type": "EXPERIMENTAL", "description": "Fimasartan 60 mg group", "interventionNames": ["Drug: Fimasartan 60 mg group"]}, {"label": "Fimasartan 2", "type": "EXPERIMENTAL", "description": "Fimasartan 120 mg group", "interventionNames": ["Drug: Fimasartan 120 mg group"]}, {"label": "Valsartan", "type": "ACTIVE_COMPARATOR", "description": "Reference (Valsartan 80 mg) group", "interventionNames": ["Drug: Reference (Valsartan 80 mg) group"]}], "interventions": [{"type": "DRUG", "name": "Fimasartan 60 mg group", "description": "Fimasartan 60 mg", "armGroupLabels": ["Fimasartan 1"], "otherNames": ["BR-A-657.K"]}, {"type": "DRUG", "name": "Fimasartan 120 mg group", "description": "Fimasartan 120 mg", "armGroupLabels": ["Fimasartan 2"], "otherNames": ["BR-A-657.K"]}, {"type": "DRUG", "name": "Reference (Valsartan 80 mg) group", "description": "Reference (Valsartan 80 mg)", "armGroupLabels": ["Valsartan"], "otherNames": ["Diovan"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change of Diastolic Blood Pressure", "description": "24hr Mean change of DBP on Week 8, from Baseline", "timeFrame": "baseline and 8 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Placebo visit and Baseline are 90\\~109mmHg inclusive and the difference between sitting diastolic blood pressures measured at Placebo visit and Baseline(Day0) is under 7mmHg.\n* Subjects who agree to participate in this sudy and give written informed consent\n* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study\n\nExclusion Criteria:\n\n* The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg Patients with secondary hypertension\n* Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug\n* Patients with postural hypotension\n* Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\\>9%, regimen change of oral hypoglycemic agents within 12weeks, treated insulin before screening)\n* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months\n* Patients with consumptive disease, autoimmune disease, connective tissue disease\n* Patients with a history of type B or C hepatitis\n* Patients with HIV or hepatitis\n* Patients with clinically significant laboratory abnormality\n* Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure\n* Patients with allergy or contraindication to any angiotensin II receptor antagonists\n* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal\n* Patients judged to have a history of alcohol or drug abuse by the investigator\n* Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Byung-He Oh, Professor", "affiliation": "Seoul National University Hospital", "role": "STUDY_CHAIR"}, {"name": "Dong-Soo Kim, Professor", "affiliation": "Inje University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Sung Chul Chae, Professor", "affiliation": "Kyungpook National University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Gi-Sik Kim, professor", "affiliation": "Daegu Catholic University Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Myung-Ho Jung, Professor", "affiliation": "Connam National University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}]}, "referencesModule": {"references": [{"pmid": "23932463", "type": "DERIVED", "citation": "Lee H, Kim KS, Chae SC, Jeong MH, Kim DS, Oh BH. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension. Clin Ther. 2013 Sep;35(9):1337-49. doi: 10.1016/j.clinthera.2013.06.021. Epub 2013 Aug 7."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Fimasartan 1", "description": "Fimasartan 60 mg group\n\nFimasartan 60 mg daily, po"}, {"id": "FG001", "title": "Fimasartan 2", "description": "Fimasartan 120 mg group\n\nFimasartan 120 mg daily, po"}, {"id": "FG002", "title": "Valsartan: Control", "description": "Reference (Valsartan 80 mg) group\n\nValsartan 80 mg daily, po"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}, {"groupId": "FG002", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}, {"groupId": "FG002", "numSubjects": "29"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Fimasartan 1", "description": "Fimasartan 60 mg group\n\nFimasartan 60 mg daily, po"}, {"id": "BG001", "title": "Fimasartan 2", "description": "Fimasartan 120 mg group\n\nFimasartan 120 mg daily, po"}, {"id": "BG002", "title": "Valsartan: Control", "description": "Reference (Valsartan 80 mg) group\n\nValsartan 80 mg daily, po"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "92"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.07", "spread": "8.36"}, {"groupId": "BG001", "value": "54.07", "spread": "8.79"}, {"groupId": "BG002", "value": "56.00", "spread": "7.15"}, {"groupId": "BG003", "value": "54.09", "spread": "8.18"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "36"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "56"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change of Diastolic Blood Pressure", "description": "24hr Mean change of DBP on Week 8, from Baseline", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "baseline and 8 Weeks", "groups": [{"id": "OG000", "title": "Fimasartan 1-ITT", "description": "Fimasartan 60 mg group\n\nFimasartan 60 mg daily, po"}, {"id": "OG001", "title": "Fimasartan 2-ITT", "description": "Fimasartan 120 mg group\n\nFimasartan 120 mg daily, po"}, {"id": "OG002", "title": "Valsartan: Control-ITT", "description": "Reference (Valsartan 80 mg) group\n\nValsartan 80 mg daily, po"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.15", "spread": "5.94"}, {"groupId": "OG001", "value": "-7.19", "spread": "9.51"}, {"groupId": "OG002", "value": "-6.70", "spread": "6.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Efficacy, Safety", "pValue": "<0.05", "statisticalMethod": "ANOVA", "statisticalComment": "comparison between the groups"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Fimasartan 1", "description": "Fimasartan 60 mg group\n\nFimasartan 60 mg daily, po", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 4, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Fimasartan 2", "description": "Fimasartan 120 mg group\n\nFimasartan 120 mg daily, po", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 5, "otherNumAtRisk": 30}, {"id": "EG002", "title": "Valsartan: Control", "description": "Reference (Valsartan 80 mg) group\n\nValsartan 80 mg daily, po", "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 2, "otherNumAtRisk": 32}], "otherEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "ALT Increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Manager of Clinical Research", "organization": "Boryung Pharmaceutical", "email": "rainbowleo@boryung.co.kr", "phone": "+82-2-708-8069"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}